PMS29 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS- A COST PER RESPONDER ANALYSIS AMONG 52 WEEKS FROM A TUNISIAN PERSPECTIVE.

Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1743
https://www.valueinhealthjournal.com/article/S1098-3015(18)35045-9/fulltext
Title : PMS29 - SECUKINUMAB VERSUS ADALIMUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS- A COST PER RESPONDER ANALYSIS AMONG 52 WEEKS FROM A TUNISIAN PERSPECTIVE.
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35045-9&doi=10.1016/j.jval.2018.09.1743
First page :
Section Title :
Open access? : No
Section Order : 1106
Categories :
Tags :
Regions :
ViH Article Tags :